Cargando…

Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer

PURPOSE: Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability–high (MSI-H) colorectal cancer (CRC), and factors predicting treatment response have not been fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyung, Jaewon, Cho, Eun Jeong, Kim, Jihun, Kim, Jwa Hoon, Kim, Jeong Eun, Hong, Yong Sang, Kim, Tae Won, Sung, Chang Ohk, Kim, Sun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582482/
https://www.ncbi.nlm.nih.gov/pubmed/35038827
http://dx.doi.org/10.4143/crt.2021.1133
_version_ 1784812848156770304
author Hyung, Jaewon
Cho, Eun Jeong
Kim, Jihun
Kim, Jwa Hoon
Kim, Jeong Eun
Hong, Yong Sang
Kim, Tae Won
Sung, Chang Ohk
Kim, Sun Young
author_facet Hyung, Jaewon
Cho, Eun Jeong
Kim, Jihun
Kim, Jwa Hoon
Kim, Jeong Eun
Hong, Yong Sang
Kim, Tae Won
Sung, Chang Ohk
Kim, Sun Young
author_sort Hyung, Jaewon
collection PubMed
description PURPOSE: Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability–high (MSI-H) colorectal cancer (CRC), and factors predicting treatment response have not been fully identified. This study aimed to identify potential biomarkers of PD-1/PD-L1 inhibitor treatment response among patients with MSI-H CRC. MATERIALS AND METHODS: MSI-H CRC patients enrolled in three clinical trials of PD-1/PD-L1 blockade at Asan Medical Center (Seoul, Republic of Korea) were screened and classified into two groups according to treatment response. Their histopathologic features and expression of 730 immune-related genes from the NanoString platform were evaluated, and a machine learning–based classification model was built to predict treatment response among MSI-H CRCs patients. RESULTS: A total of 27 patients (15 responders, 12 non-responders) were included. A high degree of lymphocytic/neutrophilic infiltration and an expansile tumor border were associated with treatment response and prolonged progression-free survival (PFS), while mucinous/signet-ring cell carcinoma was associated with a lack of treatment response and short PFS. Gene expression profiles revealed that the interferon-γ response pathway was enriched in the responder group. Of the top eight differentially expressed immune-related genes, PRAME had the highest fold change in the responder group. Higher expression of PRAME was independently associated with better PFS along with histologic subtypes in the multivariate analysis. The classification model using these genes showed good performance for predicting treatment response. CONCLUSION: We identified histologic and immune-related gene expression characteristics associated with treatment response in MSI-H CRC, which may contribute to optimal patient stratification.
format Online
Article
Text
id pubmed-9582482
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-95824822022-10-26 Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer Hyung, Jaewon Cho, Eun Jeong Kim, Jihun Kim, Jwa Hoon Kim, Jeong Eun Hong, Yong Sang Kim, Tae Won Sung, Chang Ohk Kim, Sun Young Cancer Res Treat Original Article PURPOSE: Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability–high (MSI-H) colorectal cancer (CRC), and factors predicting treatment response have not been fully identified. This study aimed to identify potential biomarkers of PD-1/PD-L1 inhibitor treatment response among patients with MSI-H CRC. MATERIALS AND METHODS: MSI-H CRC patients enrolled in three clinical trials of PD-1/PD-L1 blockade at Asan Medical Center (Seoul, Republic of Korea) were screened and classified into two groups according to treatment response. Their histopathologic features and expression of 730 immune-related genes from the NanoString platform were evaluated, and a machine learning–based classification model was built to predict treatment response among MSI-H CRCs patients. RESULTS: A total of 27 patients (15 responders, 12 non-responders) were included. A high degree of lymphocytic/neutrophilic infiltration and an expansile tumor border were associated with treatment response and prolonged progression-free survival (PFS), while mucinous/signet-ring cell carcinoma was associated with a lack of treatment response and short PFS. Gene expression profiles revealed that the interferon-γ response pathway was enriched in the responder group. Of the top eight differentially expressed immune-related genes, PRAME had the highest fold change in the responder group. Higher expression of PRAME was independently associated with better PFS along with histologic subtypes in the multivariate analysis. The classification model using these genes showed good performance for predicting treatment response. CONCLUSION: We identified histologic and immune-related gene expression characteristics associated with treatment response in MSI-H CRC, which may contribute to optimal patient stratification. Korean Cancer Association 2022-10 2022-01-12 /pmc/articles/PMC9582482/ /pubmed/35038827 http://dx.doi.org/10.4143/crt.2021.1133 Text en Copyright © 2022 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hyung, Jaewon
Cho, Eun Jeong
Kim, Jihun
Kim, Jwa Hoon
Kim, Jeong Eun
Hong, Yong Sang
Kim, Tae Won
Sung, Chang Ohk
Kim, Sun Young
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
title Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
title_full Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
title_fullStr Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
title_full_unstemmed Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
title_short Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
title_sort histopathologic and molecular biomarkers of pd-1/pd-l1 inhibitor treatment response among patients with microsatellite instability–high colon cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582482/
https://www.ncbi.nlm.nih.gov/pubmed/35038827
http://dx.doi.org/10.4143/crt.2021.1133
work_keys_str_mv AT hyungjaewon histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT choeunjeong histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT kimjihun histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT kimjwahoon histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT kimjeongeun histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT hongyongsang histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT kimtaewon histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT sungchangohk histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer
AT kimsunyoung histopathologicandmolecularbiomarkersofpd1pdl1inhibitortreatmentresponseamongpatientswithmicrosatelliteinstabilityhighcoloncancer